Month: December 2019

All haemophilia A patients in Republic of Ireland get continued access to extended half-life factor replacement therapy

Agreement has been reached on the continued provision of Extended Half Life (EHL) FVIII as an option for the treatment of Haemophilia A in Ireland for a further year to the end of 2020. The Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) have extended the contract for the supply of recombinant extended half- life …

All haemophilia A patients in Republic of Ireland get continued access to extended half-life factor replacement therapy Read More »